NO981127D0 - Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer - Google Patents

Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer

Info

Publication number
NO981127D0
NO981127D0 NO981127A NO981127A NO981127D0 NO 981127 D0 NO981127 D0 NO 981127D0 NO 981127 A NO981127 A NO 981127A NO 981127 A NO981127 A NO 981127A NO 981127 D0 NO981127 D0 NO 981127D0
Authority
NO
Norway
Prior art keywords
jgf
insulin
treatment
growth factor
factor binding
Prior art date
Application number
NO981127A
Other languages
English (en)
Norwegian (no)
Other versions
NO981127L (no
Inventor
Leonard Buckbinder
Nikolai A Kley
Bernd R Seizinger
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO981127D0 publication Critical patent/NO981127D0/no
Publication of NO981127L publication Critical patent/NO981127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO981127A 1995-09-14 1998-03-13 Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer NO981127L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US373095P 1995-09-14 1995-09-14
PCT/US1996/014623 WO1997009998A2 (fr) 1995-09-14 1996-09-12 Proteine de liaison 3 du facteur de croissance insulinoide (igf-bp3) dans le traitement de tumeurs liees a p53

Publications (2)

Publication Number Publication Date
NO981127D0 true NO981127D0 (no) 1998-03-13
NO981127L NO981127L (no) 1998-03-13

Family

ID=21707302

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981127A NO981127L (no) 1995-09-14 1998-03-13 Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer

Country Status (8)

Country Link
US (1) US5840673A (fr)
EP (1) EP0871475A2 (fr)
JP (1) JP2000502322A (fr)
AU (1) AU718451B2 (fr)
CA (1) CA2232000A1 (fr)
IL (1) IL123383A0 (fr)
NO (1) NO981127L (fr)
WO (1) WO1997009998A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO2000041730A1 (fr) 1999-01-13 2000-07-20 Meditech Research Limited Composition visant a accroitre l'efficacite de medicaments et methodes afferentes
AU3579200A (en) * 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
EP1290162A4 (fr) * 2000-05-17 2005-08-17 Univ Oregon Health Sciences Induction de l'apoptose et inhibition de la croissance cellulaire par la proteine 4.33 (p4.33)
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AU2001291090B2 (en) * 2000-09-19 2007-05-10 Bioexpertise, Llc Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
EP1435986B1 (fr) * 2001-09-18 2008-01-02 Bioexpertise, Llc Peptide derive de proteines de liaison de l'igf
WO2003068160A2 (fr) * 2002-02-13 2003-08-21 The Trustees Of Columbia University In The City Of New York Utilisation de la proteine 3 (igf-bp3) de facteur de croissance de type insuline dans le but d'inhiber la croissance d'une tumeur
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
WO2004111262A1 (fr) * 2003-06-18 2004-12-23 Pharmacia & Upjohn Company Llc Procede d'identification d'un agent chimiotherapeutique selectif
CA2541015A1 (fr) * 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
US20060084603A1 (en) * 2004-08-06 2006-04-20 Irena Kirman IGF-BP3-related methods for inhibiting tumor growth
JPWO2006070577A1 (ja) * 2004-12-28 2008-06-12 独立行政法人海洋研究開発機構 浮沈フロートおよび浮沈フロートの使用方法
EP1912658B1 (fr) * 2005-07-27 2017-01-25 Alchemia Oncology Pty Limited Protocoles thérapeutiques utilisant le hyaluronan
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT661990E (pt) * 1992-08-26 2002-09-30 Celtrix Pharma Metodo para tratamento sistemico de condicoes catabolicas e de lesoes sistemicas em tecidos
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains

Also Published As

Publication number Publication date
JP2000502322A (ja) 2000-02-29
US5840673A (en) 1998-11-24
AU6975296A (en) 1997-04-01
MX9801704A (es) 1998-05-31
WO1997009998A3 (fr) 1997-04-10
WO1997009998A2 (fr) 1997-03-20
AU718451B2 (en) 2000-04-13
EP0871475A2 (fr) 1998-10-21
NO981127L (no) 1998-03-13
IL123383A0 (en) 1998-09-24
CA2232000A1 (fr) 1997-03-20

Similar Documents

Publication Publication Date Title
NO981127D0 (no) Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer
AU3622997A (en) Fabric treatment composition
AU4861493A (en) Clear leave-on treatment composition and method
AU2065397A (en) Characterized brca1 and brca2 proteins and screening and therapeutic methods based on characterized brca1 and brca2 proteins
AU2459697A (en) Anaerobic treatment process
NO952573D0 (no) Blandinger for behandling av diabetiske komplikasjoner
AU4655296A (en) Compositions and methods for treating tumor cells
AU4230196A (en) Treatment of pancreatic tumors with peptide yy and analogs thereof
AU2189497A (en) Radiotherapy treatment using medial access transformation
AU6525296A (en) Wound treatment composition
ZA955010B (en) Enhanced crosslinking of natural tissues
EP0758196A4 (fr) Compositions et procedes de traitement de tumeurs
AUPM761094A0 (en) Treatment of hides
AU1251197A (en) Treatment of liquors
AU3040795A (en) Method and composition for treating intestinal wounds or ulcers
AU2821295A (en) Compositions and methods for the treatment of tumors
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
AU2327397A (en) Flash spinning process and flash spinning solution
AU3750395A (en) Wound treatment composition
AU1888692A (en) Composition and method for treating tumors
AU5594398A (en) Methods and compositions for preventing and treating bone loss
AU3127795A (en) Composition and treatment for baldness
AU2068295A (en) Skin treatment composition
AU6883398A (en) Methods of treating bone loss
AU7770991A (en) Method and composition for the treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application